<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003052</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065699</org_study_id>
    <secondary_id>EORTC-62961</secondary_id>
    <nct_id>NCT00003052</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma</brief_title>
  <official_title>Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The European Society for Hyperthermic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several&#xD;
      degrees above body temperature. It is not known whether receiving chemotherapy plus&#xD;
      hyperthermia is more effective than receiving chemotherapy alone in treating patients with&#xD;
      soft tissue sarcoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying combination chemotherapy alone to see&#xD;
      how well it works compared to combination chemotherapy and hyperthermia therapy in treating&#xD;
      patients with soft tissue sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine local progression-free survival of patients with high-risk soft tissue sarcoma&#xD;
           treated with neoadjuvant etoposide, ifosfamide, and doxorubicin with or without regional&#xD;
           hyperthermia.&#xD;
&#xD;
        -  Determine the tumor response rate, local disease control rate, and overall survival in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to high-risk category&#xD;
      (S1 vs S2 vs S3) and disease site (extremity vs nonextremity). Patients are randomized to one&#xD;
      of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive etoposide IV over 30 minutes on days 1 and 4, ifosfamide IV over&#xD;
           60 minutes on days 1-4, and doxorubicin IV over 30 minutes on day 1. Treatment continues&#xD;
           every 21 days for a total of 4 courses. Patients also undergo regional hyperthermia.&#xD;
&#xD;
        -  Arm II: Patients receive chemotherapy alone as in arm I. Patients in both arms undergo&#xD;
           definitive surgery 4-6 weeks after chemotherapy. Patients also undergo radiotherapy&#xD;
           beginning 4-6 weeks after surgery. After completion of surgery and radiotherapy,&#xD;
           patients with non-resectable tumors showing no disease progression receive an additional&#xD;
           4 courses of chemotherapy with or without regional hyperthermia according to above&#xD;
           treatment schedule.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 4 months for 2 years, and then every 6&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 340 patients (170 patients per arm) will be accrued for this&#xD;
      study within 3.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Local progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response as assessed by WHO criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late complications as assessed by CTC v 1.0</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermia treatment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven grade II or III soft tissue sarcoma of one of following&#xD;
             high-risk groups:&#xD;
&#xD;
               -  Grade II/III primary tumor with lesion size of at least 5 cm, deep, and&#xD;
                  extracompartmental (S1)&#xD;
&#xD;
               -  Local recurrence of primary tumor (S2)&#xD;
&#xD;
               -  Inadequate surgical excision of S1 or S2 (S3)&#xD;
&#xD;
          -  Disease recurrence after prior surgery allowed&#xD;
&#xD;
          -  The following histological types are eligible:&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Liposarcoma (round cell and pleomorphic)&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Malignant paraganglioma&#xD;
&#xD;
               -  Neurofibrosarcoma (malignant schwannoma)&#xD;
&#xD;
               -  Extraskeletal Ewing's sarcoma&#xD;
&#xD;
               -  Extraskeletal osteosarcoma&#xD;
&#xD;
               -  Malignant peripheral neuroectodermal tumors&#xD;
&#xD;
               -  Mesenchymal chondrosarcoma&#xD;
&#xD;
               -  Angiosarcoma&#xD;
&#xD;
               -  Miscellaneous sarcoma&#xD;
&#xD;
               -  Unclassified sarcoma&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.25 times upper limit of normal&#xD;
&#xD;
          -  No severe hepatic dysfunction&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No chronic renal failure&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No documented existing cardiac failure&#xD;
&#xD;
          -  No manifest heart failure (New York Heart Association class III or IV)&#xD;
&#xD;
          -  Left ventricular ejection fraction no more than 10% below institutional normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other severe disease&#xD;
&#xD;
          -  No severe cerebrovascular disease&#xD;
&#xD;
          -  No extremely obese patients&#xD;
&#xD;
          -  No prior metallic implants relevant to the regional hyperthermia field&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy (except to disease recurrence outside study irradiation field)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior mutilative surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <affiliation>Klinikum der Universitaet Muenchen - Grosshadern Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universitaet Muenchen - Grosshadern Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Stahl R, Wang T, Lindner LH, Abdel-Rahman S, Santl M, Reiser MF, Issels RD. Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). Int J Hyperthermia. 2009 Jun;25(4):289-98. doi: 10.1080/02656730902873616.</citation>
    <PMID>19670096</PMID>
  </reference>
  <results_reference>
    <citation>Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Durr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561-70. doi: 10.1016/S1470-2045(10)70071-1. Epub 2010 Apr 29.</citation>
    <PMID>20434400</PMID>
  </results_reference>
  <results_reference>
    <citation>Issels RD, Lindner LH, Wust P, et al.: Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros. [Abstract] J Clin Oncol 25 (Suppl 18): A-10009, 547s, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Lindner LH, Schlemmer M, Hohenberger P, et al.: Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy regional hyperthermia: EORTC 62961/ESHO-RHT 95 intergroup phase III study. [Abstract] J Clin Oncol 23 (Suppl 16): A-9020, 821s, 2005.</citation>
  </results_reference>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>adult extraskeletal osteosarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>stage I adult soft tissue sarcoma</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

